A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Status:
Recruiting
Trial end date:
2029-11-29
Target enrollment:
Participant gender:
Summary
The study has been designed with two components. Part A is an open label PK study followed by
a randomized trial component (Part B). The initial PK analysis is first done in adolescent
subjects (12 to <18 years) before initiating the PK study in younger cohort (6 to <12 years)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Pharma Global FZE Sun Pharmaceutical Industries Limited